How NEU-002 could reshape Onchilles Pharma’s systemic solid tumor strategy after AACR 2026
Onchilles Pharma’s NEU-002 showed systemic anti-tumor activity at AACR 2026. Read what the preclinical data could mean for solid tumor development.
Pharma & Biotech